{"id":728552,"date":"2023-02-03T07:04:22","date_gmt":"2023-02-03T12:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/"},"modified":"2023-02-03T07:04:22","modified_gmt":"2023-02-03T12:04:22","slug":"celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/","title":{"rendered":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023"},"content":{"rendered":"<h2>\nCompany to host webcast on Sunday, February 26 at 4:00 pm CT\/5:00 pm ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">HAMPTON, N.J., Feb.  03, 2023  (GLOBE NEWSWIRE) &#8212; Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company\u2019s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February 3, 2023.<\/p>\n<p>Presentation Details:<\/p>\n<p>\n        <strong>Session Date &amp; Time:<\/strong> Sunday, February 26th at 9:45 am &#8211; 10:45 am CT (10:45 am ET \u2013 11:45 am ET)<br \/><strong>Poster No. 308:<\/strong> Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria<br \/><strong>Presenting Author:<\/strong> Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charit\u00e9 &#8211; Universit\u00e4tsmedizin in Berlin<\/p>\n<p>Data included in the abstract are through May 2022. New data will be presented at the AAAAI meeting and will include the following:<\/p>\n<ul type=\"disc\">\n<li>Data through 24 weeks for Cohorts 1-3 (0.5, 1.5 and 3.0 mg\/kg doses)<\/li>\n<li>Data through 20 weeks for Cohort 4 (4.5 mg\/kg dose); 6 of 9 patients\u00a0available at this timepoint as of the data cut-off date<\/li>\n<\/ul>\n<p>\n        <strong>Webcast and Conference Call<\/strong><br \/>\n        <br \/>The Company will host a webcast presentation of the data on Sunday, February 26<sup>th<\/sup> at 4:00 pm CT (5:00 pm ET). The event will be webcast live and can be accessed by going to the &#8220;Events &amp; Presentations\u201d page under the &#8220;Investors &amp; Media&#8221; section of the Celldex Therapeutics website at www.celldex.com.<\/p>\n<p>\n        <strong>About Celldex Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and\/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L62UVtj5ebFqnkqZjwYjkO2FeOIVRdXqhdK3-4uEjhNwcosv6LpC0HSvx2X44mgRswhFvEDEUtIdH_biymeAhA==\" rel=\"nofollow noopener\" target=\"_blank\">www.celldex.com<\/a>.<\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Sarah Cavanaugh<br \/>Senior Vice President, Corporate Affairs &amp; Administration<br \/>(508) 864-8337<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ESzp2p9ibCzzKs39uTRN8_Xdh1MvBYAEi7ok0tzcLMp6NcM7PGHvXXjOhd2gF8nL9FCUpI_C-HdLOV0uijhj5F484XdfhOjohsfv3OrA8dY=\" rel=\"nofollow noopener\" target=\"_blank\">scavanaugh@celldex.com<\/a><\/p>\n<p>Patrick Till<br \/>Meru Advisors<br \/>(484) 788-8560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fFVGxn0BRimST_2S3kLbTqKPJaAuy13xMR3ecBqqTFyMSxl7F2Ac68hQuZEBdOc-rVQA8KtAiqo__xleSwioUSwd5TGxo7zQEtvxqX9WYww=\" rel=\"nofollow noopener\" target=\"_blank\">ptill@meruadvisors.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTUwMTlmZmYtNTY4MS00NmMyLTg5MTItNTkxZDMyMDcwZDUxLTEwMTY3NjI=\/tiny\/Celldex-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to host webcast on Sunday, February 26 at 4:00 pm CT\/5:00 pm ET HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company\u2019s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February 3, 2023. Presentation Details: Session Date &amp; Time: Sunday, February 26th at 9:45 am &#8211; 10:45 am CT (10:45 am ET \u2013 11:45 am ET)Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728552","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host webcast on Sunday, February 26 at 4:00 pm CT\/5:00 pm ET HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company\u2019s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February 3, 2023. Presentation Details: Session Date &amp; Time: Sunday, February 26th at 9:45 am &#8211; 10:45 am CT (10:45 am ET \u2013 11:45 am ET)Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic &hellip; Continue reading &quot;Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T12:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023\",\"datePublished\":\"2023-02-03T12:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/\"},\"wordCount\":352,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/\",\"name\":\"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=\",\"datePublished\":\"2023-02-03T12:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/","og_locale":"en_US","og_type":"article","og_title":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 - Market Newsdesk","og_description":"Company to host webcast on Sunday, February 26 at 4:00 pm CT\/5:00 pm ET HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company\u2019s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February 3, 2023. Presentation Details: Session Date &amp; Time: Sunday, February 26th at 9:45 am &#8211; 10:45 am CT (10:45 am ET \u2013 11:45 am ET)Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic &hellip; Continue reading \"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-03T12:04:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023","datePublished":"2023-02-03T12:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/"},"wordCount":352,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/","name":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=","datePublished":"2023-02-03T12:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE5MyM1MzkwMDc5IzIwMDUxODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in-chronic-spontaneous-urticaria-at-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728552"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728552\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}